Three-Dimensional Automated, Machine-Learning-Based Left Heart Chamber Metrics: Associations with Prevalent Vascular Risk Factors and Cardiovascular Diseases

Abstract

Background. Three-dimensional transthoracic echocardiography (3DE) powered by artificial intelligence provides accurate left chamber quantification in good accordance with cardiac magnetic resonance and has the potential to revolutionize our clinical practice. Aims. To evaluate the association and the independent value of dynamic heart model (DHM)-derived left atrial (LA) and left ventricular (LV) metrics with prevalent vascular risk factors (VRFs) and cardiovascular diseases (CVDs) in a large, unselected population. Materials and Methods. We estimated the association of DHM metrics with VRFs (hypertension, diabetes) and CVDs (atrial fibrillation, stroke, ischemic heart disease, cardiomyopathies, >moderate valvular heart disease/prosthesis), stratified by prevalent disease status: participants without VRFs or CVDs (healthy), with at least one VRFs but without CVDs, and with at least one CVDs. Results. We retrospectively included 1069 subjects (median age 62 [IQR 49–74]; 50.6% women). When comparing VRFs with the healthy, significant difference in maximum and minimum indexed atrial volume (LAVi max and LAVi min), left atrial ejection fraction (LAEF), left ventricular mass/left ventricular end-diastolic volume ratio, and left ventricular global function index (LVGFI) were recorded (p < 0.05). In the adjusted logistic regression, LAVi min, LAEF, LV ejection fraction, and LVGFI showed the most robust association (OR 3.03 [95% CI 2.48–3.70], 0.45 [95% CI 0.39–0.51], 0.28 [95% CI 0.22–0.35], and 0.22 [95% CI 0.16–0.28], respectively, with CVDs. Conclusions. The present data suggested that novel 3DE left heart chamber metrics by DHM such as LAEF, LAVi min, and LVGFI can refine our echocardiographic disease discrimination capacity.

A sensitivity indicator screening and intelligent classification method for the diagnosis of T2D-CHD

“…For instance, the work of Alimova et al, employing ML algorithms to predict diastolic dysfunction in cardiovascular and diabetic patients, highlights the precision and effectiveness these technologies bring to medical diagnostics ( 14 ). This is further supported by research from Saeed and Hama, who explored cardiac disease prediction using AI algorithms ( 15 ), and from Chinmayi et al and Barbieri et al, who delved into AI's role in disease risk prediction and the utilization of advanced imaging techniques for enhanced diagnostic accuracy ( 16 , 17 ). These studies underscore the adaptability and depth of AI/ML in capturing complex cardiovascular and metabolic interrelations, setting a foundation for our methodology.…”

Development and trends in research on hypertension and atrial fibrillation: A bibliometric analysis from 2003 to 2022

“…Artificial intelligence (AI)-based systems have been widely applied in cardiovascular imaging and cardiovascular disease risk prediction, leading to significant advancements in various aspects of the medical domain. [53][54][55] Ebrahimzadeh et al conducted a smallscale study aiming to predict atrial fibrillation by analyzing heart rate variability in 53 patients' electrocardiogram records using machine learning techniques. [56] Another bioinformatics-based study utilized the Gene Expression Omnibus database for microarray meta-analysis to identify differentially expressed genes.…”

Artificial Intelligence in Cardiology: Why So Many Great Promises and Expectations, but Still a Limited Clinical Impact?

“…In the echocardiographic field, AI may improve imaging quality, guiding scanning, and assisting in segmentation, processing, and analysis [ 1 , 2 , 3 , 4 , 5 ]. AI can help in view interpretation and classification, in the quantification of both cardiovascular structure and function, and in detecting wall motion abnormalities [ 1 , 2 , 3 , 4 , 5 ].…”

“…In the echocardiographic field, AI may improve imaging quality, guiding scanning, and assisting in segmentation, processing, and analysis [ 1 , 2 , 3 , 4 , 5 ]. AI can help in view interpretation and classification, in the quantification of both cardiovascular structure and function, and in detecting wall motion abnormalities [ 1 , 2 , 3 , 4 , 5 ]. AI can also help differentiating physiological hypertrophy in athletes from hypertrophic cardiomyopathy, and in the identification and assessment of amyloidosis, pulmonary artery hypertension, and valvular heart disease, as mitral regurgitation and aortic stenosis [ 1 , 2 , 3 , 4 , 5 ].…”